Perspective · 2 Feb 2026
Conference abstractPublished 29 Feb 2016
Ad-RTS-hIL-12+Veledimex bench to bedside in the treatment of metastatic breast cancer
Ziopharm Oncology Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Immunotherapy has been shown to be effective in breast cancer patients. In breast cancer, CD8+ T-cells are activated by IL-12 have been shown to correlate with anti-tumor activity and prolonged survival. Ad-RTS-IL-12 (Ad) is a replication incompetent adenovirus engineered to express IL-12 via our RheoSwitch Therapeutic SystemÃ?® gene switch. When injected directly into a tumor. IL-12 expression is off devoid of the activator ligand, veledimex (V), while IL-12 production is turned on in a dose-dependent manner by V p.o. Mechanistic studies in the 4T1 syngeneic mouse breast tumor model with Ad+V have shown a dose related increase in tumor IL-12 mRNA and IL-12 protein expression. Cessation of V resulted in a return to baseline IL-12 mRNA and IL-12 protein expression. These changes correlated with a local and systemic immune and anti tumor response. Low dose chemotherapy primes the immune system and in combination with immunotherapy may augment tumor specific T-cells resulting in enhanced efficacy. In the 4T1 mouse mammary tumor model Ad (1e10vp)+V (30 mg/m2) with low dose chemotherapy significantly inhibited tumor growth in a supra-additive fashion concomitant with increased median survival vs. single agent alone. Based on these results an open label, phase-2 trial evaluating the safety of inducible IL-12 expression in heavily pretreated subjects with recurrent/metastatic breast cancer was performed. In this study, treatment with Ad+V resulted in increase in IL-12, downstream IFNg followed by rapid increase in IL-10 and IP-10. In the 12 subjects administrated Ad+V there was a total of 16 non-injected evaluable lesions in 7 subjects. Of the 16 lesions, 1 lesion had decrease in lesion diameter ranging from 10-19%, 2 lesions 30-49% and 3 lesions 50-100%. Most common âÂ?¥Grade 3 treatment emergent adverse events in BC and melanoma included neutropenia and hyponatremia (16% each), hypotension, cytokine release syndrome, AST increase (11% each), dehydration, fatigue, pyrexia (8% each). All TEAEs and SAEsâÂ?¥Grade 3 reversed rapidly upon discontinuation of veledimex. The results of this study showed biologic activity with an acceptable therapeutic index. In summary, Ad+V are a novel gene therapy which controls local expression of IL-12, which may result in the collapse of tumor stroma and stimulating an anti-cancer T-cell immune response. The ability to regulate the production of IL-12 by modulating V dosing may result in an improved therapeutic index in combination with standard of care.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cell Science & Therapy.
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “John A Barrett”
- BylineArticles whose byline prints “H Cai”
- BylineArticles whose byline prints “J Miao”
- BylineArticles whose byline prints “F Lebel”

